Framework agreement for the purchase of aflibercept and ranibizumab

Summary

Universitair Ziekenhuis Brussel is procuring aflibercept and ranibizumab in pre-filled syringes for intravitreal administration under a two-lot framework agreement. The aflibercept lot covers an estimated 190 units per year, or 760 units over four years; the notice does not specify the quantity for ranibizumab. The framework agreement has a maximum total value of EUR 1,840,128.28 and is planned to run from 8 January 2027 to 7 January 2031.